Association of FXIII Va134Leu with decreased risk of myocardial infarction in finnish males

Atherosclerosis

Volumn 142, Issue 2, 1999, Pages 295-300

  Wartiovaara, U ^a   Perola, M ^b   Mikkola, H ^a   Totterman K ^c   Savolainen, V ^a   Penttila A ^a   Grant, P J ^d   Tikkanen, M J ^c   Vartiainen, E ^b   Karhunen, P J ^e   Peltonen, L ^b   Palotie, A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Blood coagulation factor XIII; Coronary disease; Finland; Genetics; Myocardial infarction

Indexed keywords

BLOOD CLOTTING FACTOR 13; FIBRIN; LEUCINE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; VALINE; DNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRIMER DNA;

ADULT; ALLELE; ARTICLE; BLOOD CLOTTING; CORONARY ARTERY DISEASE; FINLAND; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; POINT MUTATION; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS; CHEMISTRY; COMPARATIVE STUDY; FIBRINOLYSIS; GENETIC MARKER; GENETICS; INCIDENCE; MIDDLE AGED; PREVALENCE;

ALLELES; DNA; DNA PRIMERS; FACTOR XIII; FIBRINOLYSIS; FINLAND; GENETIC MARKERS; GENOTYPE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PREVALENCE; RISK FACTORS;

EID: 0032588857     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00241-X     Document Type: Article

References (20)

1. Muszbek L., Laki K. Interaction of thrombin with proteins other than fibrinogen (thrombin susceptible bonds). Activation of factor XIII. Machovich R. The Thrombin. 1984;83-102 CRC Press, Boca Raton, FL.
2. Mikkola H., Syrjälä M., Rasi V., Vahtera E., Peltonen L., Palotie A. Deficiency in the A-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levels. Blood. 84:1994;517-525.
3. Mikkola H., Yee V.C., Syrjälä M., Seitz R., Egbring R., Petrini P., Ljung R., Ingerslev J., Teller D.C., Peltonen L., Palotie A. Four novel mutations in deficiency of coagulation factor XIII: consequences to expression and structure of the A-subunit. Blood. 87:1996;141-151.
4. Mikkola H., Muszbek L., Laiho E., Syrjälä M., Hämäläinen E., Haramura G., Salmi T., Peltonen L., Palotie A. Molecular mechanism of a mild phenotype in coagulation factor XIII (FXIII) deficiency: a splicing mutation permitting correct splicing of FXIII A-subunit mRNA. Blood. 89:1997;1279-1287.
5. Mikkola H., Muszbek L., Haramura G., Hämäläinen E., Jalanko A., Palotie A. Molecular mechanisms of mutations in factor XIII A-subunit deficiency: in vitro expression in COS-cells demonstrates intracellular degradation of the mutant proteins. Thromb Haemostasis. 78:1997;1068-1074.
6. Kohler H.P., Stickland M.H., Ossei-Gerning N., Carter A., Mikkola H., Grant P.J. Association of a common polymorphism in the Factor XIII Gene with myocardial infarction. Thromb Haemostasis. 79:1998;8-13.
7. Vartiainen E., Puska P., Pekkanen J., Tuomilehto J., Jousilahti P. Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland. Brit Med J. 309:1994;23-27.
8. Peltonen L., Pekkarinen P., Aaltonen J. Messages from an isolate: lessons from the Finnish gene pool. Biol Chem H-S. 376:1995;697-704.
9. Karhunen P.J., Männikkö A., Penttilä A., Liesto K. Diagnostic angiography in postoperative autopsies. Am J Forensic Med Pathol. 10:1989;303-309.
10. Frick M.H., Dahlen G., Berg K., Valle M., Hekali P. Serum lipids in angiographically assessed coronary atherosclerosis. Chest. 73:1978;62-85.
11. Heliö T., Palotie A., Tötterman K.J., Ott J., Kauppinen-Mäkelin R., Tikkanen M. Lack of association between the apolipoprotein B gene 3′ hypervariable region alleles and coronary artery disease in Finnish patients with angiographically documented coronary artery disease. J Int Med. 231:1992;49-57.
12. Rose G., Blackburn H. Classifications of the electrocardiogram in population studies. Cardiovascular survey methods. 1968;137-154 World Health Organisation, Geneva.
13. Syvänen A.C., Aalto S.K., Harju L., Kontula K., Söderlund H. A primer-guided nucleotide incorporation assay in the genotyping of apolipoprotein E. Genomics. 8:1990;684.
14. Ihalainen J., Siitari H., Laine S., Syvänen A.C., Palotie A. Towards automatic detection of point mutations: use of scintillating microplates in solid-phase minisequencing. BioTechniques. 16:1994;938-943.
15. 2+/dextran sulfate in its enzymic measurement. Clin Chem. 24:1978;931-933.
16. Syvänen A.C., Sajantila A., Lukka M. Identification of individuals by analysis of biallelic DNA markers, using PCR and solid-phase minisequencing. Am J Hum Genet. 52:1993;46-59.
17. Vartiainen E., Puska P., Jousilahti P., Korhonen H.J., Tuomilehto J., Nissinen A. Twenty-year trends in coronary risk factors in North Karelia and in other areas of Finland. Int J Epidemiol. 23:1994;495-504.
18. Kittles R.A., Perola M., Peltonen L., Bergen A.W., Aragon R.A., Virkkunen M., Linnoila M., Goldman D., Long J.C. Dual origins of Finns revealed by Y chromosome haplotype variation. Am J Hum Genet. 62:1998;1171-1179.
19. Burzotta F., Dicastelnuovo A., Amore C., Dorazio A., Donati M.B., Iacoviello L. 4G/5G polymorphism in the promoter region of the PAI-1 gene is not a risk factor for familial myocardial infarction in subjects over 45 years. Thromb Haemostasis. 78:1997;1294-1295.
20. Colaizzo D, Margaglione M, Lirato C, Grandone E, Cappucci G, Fischetti A, Mancini FP, Pauciullo P, Di Minno G. Plasminogen activator inhibitor-1 4G/5G polymorphism in subjects with a history of juvenile coronary heart disease.Thromb Haemostasis 1997; suppl 97 (abstract).